Plant to product – some thoughts

David G. Elliott

B.A. (Lon) MBA Executive

Management (Hull) MCIM

Brand Owners in the Doldrums?

• Pressure from retailers restricts R&D.

• Without exciting products de-listing an ever

present threat.

• R&D typically 1% (Pharma 18%) of sales.• R&D typically 1% (Pharma 18%) of sales.

• Need to improve quantum and quality of R&D.

• Open Innovation – P&G, Reckitt Benckiser etc.

Complex.

Value Chains

• Can be a long journey.

• Need for evidence – trials, human studies etc.

• Supply should not be in one Company ideally.

What does this mean?

• Supply should not be in one Company ideally.

• Some ideas more market ready than others.

• Skin care may be point of entry.

• Stamina needed.

Sativex® is a cannabinoid medicine for the

treatment of spasticity due to multiple sclerosis

which is also in development in cancer pain and

Some examples

which is also in development in cancer pain and

neuropathic pain of various origins..

Registered in 25 countries for MS.

Some examples

• Nivea • Sea buckthorn

Some examples

• Traditional.

• Mature.

• Well known.

Some examples

• Gaviscon • Long history.

• Many variants

• CE mark if launched today?launched today?

Some examples

• US Product • Role in diabetes foot care?

Must be ‘World Class’

• Must offer significant added value – unmet need.

• Some ground breaking innovations will not prove successful.prove successful.

• World wide potential demands ability to scale up.

• Open Innovation/Partnerships etc.

The Future

• Innovation likely to come from SMEs with links

to big Corporate via Open Innovation networks.

• The big will get stronger leveraging brand

power across multiple markets.power across multiple markets.

• May be need to use OI intermediaries etc.

• Crowd funding?

• Protein from algae?

Thank you

• Questions?